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The prevention of extracorporeal clotting during 
hemodialysis maximizes the effectiveness of treat- 
ment by maintaining patency in the dialyzer blood 
compartment and thereby obviating several impor- 
tant consequences. For example, clotting leads di- 
rectly to blood loss, as much as 200-300 ml for each 
episode, depending on the total volume of the extra- 
corporeal circuit. In addition, clotting reduces dialy- 
zer clearance and thus the adequacy of dialysis treat- 
ment. Finally, clotting increases the overall cost and 
complications of hemodialysis. 
Prevention of clotting during extracorporeal di- 
alysis procedures is accomplished successfully in 
most instances using intermittent systemic heparin- 
ization and hemodialysis sometimes can be accom- 
plished without anticoagulation at all (1, 2). How- 
ever, occasional patients manifest extreme resistance 
to heparin and suffer vascular access thrombosis or 
recurrent severe clotting of the extracorporeal circuit. 
Although the latter phenomenon, severe clotting of 
the extracorporeal circuit, is observed infrequently 
(3, 4), it is striking and problematic when it occurs. 
In evaluating possible causes and appropriate treat- 
ments for such clotting, several important factors 
which must be considered include: the characteristics 
of the extracorporeal circuit and its components, 
intrinsic abnormalities in circulating coagulation fac- 




Mechanical Reduction of Blood Flow 
The most common cause of increased clotting in 
the extracorporeal circuit during hemodialysis is re- 
duction in blood flow, usually the result of mechan- 
ical abnormalities in the vascular access or in the 
extracorporeal circuit itself (3, 4). Most often such 
abnormalities are easily detected, although reduced 
blood flow may be more subtle in settings such as 
continuous arterio-venous hernofiltration in which 
neither blood pump nor pressure and flow monitors 
are employed. Therefore, mechanical reduction in 
blood flow should always be considered when inor- 
dinate clotting has occurred during hemodialysis or 
related procedures. 
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Interaction of Blood and Synthetic Materials 
Extracorporeal circulation of blood in synthetic 
tubing and devices can lead to activation of circulat- 
ing inflammatory mediators such as complement 
components and formed elements in the blood such 
as WBC and platelets. This activation can occur with 
or without heparin and is associated with platelet 
aggregation, reduced platelet count and fibrin accu- 
mulation on the dialyzer membranes (5-9). 
These interactions are thought to depend on the 
adsorption of plasma proteins on the surface of the 
dialyzer membrane (lo), and it appears that the 
specific type of membrane may be important. For 
example, cuprophane dialyzers appear to be associ- 
ated with more heparin resistance and platelet con- 
sumption when compared with polyacrylonitrile, 
polysulfone or polymethylmalonylacetate dialyzers 
(9, 1 1-16). Furthermore, even the composition of 
the blood tubing may be implicated, and tubing 
composed of silicone rubber may be associated with 
platelet and fibrin accumulation in excess of that 
observed using other plastic materials ( 17). 
One other physical factor sometimes thought to 
contribute to dialyzer clotting is low dialysate pH 
( 18), a consideration when using sorbent or bicar- 
bonate dialysis systems in which dialysate pH may 
be subphysiologic at times. Finally, there is some 
evidence linking higher hematocrit to both improved 
bleeding time and platelet function as well as extra- 
corporeal fibrin deposition (1 9-2 1). This association 
of hypercoagulability with increased hematocrit may 
counter some of the clinical benefits of erythropoie- 
tin administration in hemodialysis patients. 
Circulating Coagulation Cofactors 
In addition to the extracorporeal factors and inter- 
actions with synthetic materials, there are also rec- 
ognized abnormalities in several intrinsic coagula- 
tion factors which might be associated with hyper- 
coagulability and which have been described in 
hemodialysis patients. First among these factors is 
antithrombin I11 (AIII), a 65 kilodalton protease 
inhibitor synthesized in the liver. Low levels of A111 
activity may occur in patients with hereditary defects 
in liver synthesis of AIII, with increased A111 con- 
sumption due to extensive intravascular thrombosis 
or to ongoing heparin administration, and with in- 
creased urinary A111 loss in nephrotic syndrome (22- 
24). Familial A111 deficiency has been noted with a 
frequency of 1 in 2000-5000 of the general popula- 
tion, and most often involves a reduction below 
normal in circulating A111 activity of less than 30% 
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(22). A moderate increase in heparin resistance has 
been associated with a 40-60% reduction in AIII 
activity in familial cases, while severe resistance has 
been noted when A111 is reduced by more than 60% 
(22, 23). 
Studies in dialysis patients suggest that, in general, 
AIII levels may be somewhat low (25-27) and that 
levels may fall slightly during hemodialysis (27, 28); 
however, the extent of these changes is small and 
does not ordinarily result in coagulation abnormali- 
ties. Several individual cases of severe A111 deficiency 
associated with severe clotting have been reported 
among hemodialysis patients (29). Therefore, AIII 
deficiency should be considered when severe extra- 
corporeal clotting occurs, particularly when mechan- 
ical causes of reduced blood flow cannot be identified 
and when renal failure is associated with underlying 
nephrotic syndrome. 
Other plasma cofactors associated with hyperco- 
agulability include protein C, a vitamin K dependent 
plasma protein which can neutralize factors V and 
VIII, and protein S .  Relatively low circulating levels 
of protein C in uremic patients, levels which may 
decrease further following hemodialysis, are thought 
to reflect platelet activation and thrombin generation 
during the dialysis procedure (30-32). Nonetheless, 
specific reports of hypercoagulability due to protein 
C or protein S deficiency among hemodialysis pa- 
tients are anecdotal at best and require further con- 
firmation (33). Other reports suggesting an addi- 
tional role for protein C or protein S deficiency in 
the syndrome of skin necrosis with systemic calci- 
phylaxis (34) leave open the possible pathogenetic 
effect of hypercoagulability in causing small vessel 
thrombosis among dialysis patients. If such patho- 
genetic mechanisms prove true, then abnormalities 
in protein C and protein S metabolism may well be 
implicated in many instances of hypercoagulability 
among hemodialysis patients. 
Pharmacologic Agents 
Circumstances arise in which pharmacologic 
agents appear to activate the coagulation system and 
result in increased clotting. For example, agents such 
as conjugated estrogens and DDAVP, which im- 
prove the bleeding time in uremic patients, have 
been associated with hypercoagulability and exces- 
sive clotting in hemodialysis patients (35, 36). In 
addition, erythropoietin treatment for the anemia of 
chronic renal failure has also been shown to improve 
platelet function among dialysis patients and, there- 
fore, to be associated with possible enhancement of 
thrombosis (2 1, 37). 
Heparin itself has even been associated with im- 
munologic activation of platelets and resulting 
thrombocytopenia (38, 39). Furthermore, some au- 
thors feel that heparin may be responsible for the 
hypercoagulability associated with syndromes such 
as priapism in the hemodialysis setting (40). How- 
ever, evidence suggests that hypercoagulability due 
to heparin-related platelet activation is very unusual 
in the general hemodialysis population (4 1). Finally, 
agents such as nitroglycerin have been reported to 
interfere with the anticoagulant activity of heparin 
and to be responsible for hypercoagulability in the 
non-dialysis setting (42); thus, surveillance for such 
phenomena in the dialysis setting is warranted. 
Other Clinical Settings 
Hypercoagulability has also been described in set- 
tings of striking general illness, such as septicemia, 
circulatory collapse, and malignancy, with or with- 
out the presence of renal failure or dialysis (43). To 
date no particular predisposition to hypercoagulabil- 
ity has been ascribed to renal failure or dialysis in 
these severe conditions, but it seems reasonable to 
expect an increased tendency toward clotting when 
severe illness complicates acute or chronic renal 
failure. 
Diagnosis and Treatment 
The management of extracorporeal clotting asso- 
ciated with hemodialysis ordinarily involves increas- 
ing the heparin dosage. However, the need to in- 
crease heparin dosage presents the clinician with a 
particular challenge when there is an increased risk 
for bleeding in a dialysis patient, since heparin will 
potentiate the likelihood of bleeding from any intra- 
corporeal sites (3,4). Therefore, because mechanical 
reduction of blood flow most often causes extracor- 
poreal clotting and will not be amenable to increased 
heparin, it is appropriate to evaluate for extracor- 
poreal occlusion or for correctable lesions such as 
stenosis of the vascular access before increasing hep- 
arin dosage. 
Unusual cases in which specific cofactor abnor- 
malities are identified may be amenable to replace- 
ment therapy. For example, treatment using syn- 
thetic A111 has been described in hemodialysis pa- 
tients with low AIII activity (44). Alternatively, 
agents which inhibit platelet activation, particularly 
short-acting parenteral agents such as prostacyclin 
(45-47) or longer-acting agents such as sulfinpyra- 
zone (48, 49), might be useful when hypercoagula- 
bility is associated with hyperaggregability. In some 
instances, the use of dialyzer membranes such as 
polyacrylonitrile which do not acutely activate in- 
flammatory mediators (9, 1 1-16) may also prove 
useful in such hypercoagulable patients. 
When heparin itself appears to contribute to the 
hypercoagulability, or when the pathogenesis is un- 
clear, alternative methods for preventing extracor- 
poreal clotting might prove useful. For example, low 
molecular weight heparinoids may avoid immuno- 
genicity and prove more effective in some circum- 
stances (50), although the specific use of these agents 
under circumstances of hypercoagulability in he- 
modialysis has not been reported. Another alterna- 
tive to heparin use is regional anticoagulation using 
citrate plus calcium neutralization in hemodialysis 
( 5  1) or in continuous arteriovenous hernofiltration 
(52). Finally, there are reports describing membrane 
materials which are bonded with heparin itself to 
retard clotting (53), or with heparinase (54) or prot- 
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amine ( 5 5 )  which removes circulating heparin at the 
time of blood return. However, the clinical utility of 
these latter materials for general use is yet to be 
demonstrated. 
Conclusion 
Unfortunately, no single predominant pathoge- 
netic entity causing hypercoagulability has been de- 
scribed in the dialysis setting. Therefore, no consist- 
ently successful or clearly indicated method for treat- 
ing or preventing such hypercoagulability is yet 
available. In the meantime, rigorous clinical surveil- 
lance for abnormalities such as those outlined here 
may help to define at least a subset of patients for 
whom both pathogenesis as well as directed therapy 
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